FOLH1 and metastatic prostate carcinoma: In particular, prostate-specific membrane antigen (PSMA) ligands labelled with 225Ac have shown remarkable therapeutic efficacy with complete radiological response in patients with metastatic prostate cancer, even when 177Lu-labelled analogues had failed [6,7].